SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.

Raymond T SuhandynataNicholas J BevinsJenny T TranDeli HuangMelissa A HoffmanKyle LundMichael J KelnerRonald W McLawhonSteven L GoniasDavid NemazeeRobert L Fitzgerald

Published in: The journal of applied laboratory medicine (2021)

The Roche S-antibody and Diazyme NAbs assays robustly detected adaptive immune responses in SARS-CoV-2 vaccinated individuals and SARS-CoV-2 infected individuals. The Diazyme NAbs assay strongly correlates with the PSV SARS-CoV-2 NAbs in vaccinated individuals. Understanding the reactivity of commercially available serology platforms is important when distinguishing vaccination response versus natural infection.

Keyphrases

sars cov
immune response
respiratory syndrome coronavirus
high throughput
dendritic cells
coronavirus disease